Bailard, Inc. Viridian Therapeutics, Inc.\De Transaction History

Bailard, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$10.69 - $18.2 $967,445 - $1.65 Million	-90,500 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$14.34 - $18.67 $293,970 - $382,735	-20,500 Reduced 18.47%	90,500 $1.66 Million
Q1 2021 May 13, 2021	BUY	$15.5 - $24.93 $1.72 Million - $2.77 Million	111,000 New	111,000 $1.86 Million

179

76.6M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $805M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.